This finding is similar to our previous observations following rigosertib treatment of hematologic cancer cell lines [19, 26] and suggests that inhibition of Mcl-1 is a central mechanism by which rigosertib activates programmed cell death in cancer cells. Here, MCL1 is linked to hematopoietic and lymphoid cell neoplasm.